Last month, the Biotech Daily Top 40 Index (BDI-40) improved $1,536 million or 7.6 percent to a collective market capitalization of $21,756 million. Today, the BDI-40 is down $1,125 million or 5.2 percent, not quite wiping off last month’s recovery.

Meanwhile, the benchmark ASX200 fell 3.0 percent to 8,614 points in November and the Nasdaq Biotechnology Index climbed 8.4 percent to 5,818 points.

CSL recovered $3,211 million or 3.7 percent of last month’s fall, following the anti-vaccination campaign by US President Donald Trump and his Secretary for Health Robert Kennedy, helping the collective value of the four Big Caps of Cochlear, CSL, Pro Medicus and Resmed (which are not included in the BDI-40) up 1.5 percent to $193,915 million.

Pro Medicus improved 1.3 percent to $27,872 million; while Resmed slipped 0.5 percent to $57,379 million and Cochlear fell 1.7 percent to $18,339 million.

For the 40 companies in the BDI-40, November was a fairly even month, with 19 companies up – of which six were up by more than 10 percent – and 19 companies down – with 12 companies falling more than 10 percent.

Mesoblast added the most to the index, up $231 million or 7.2 percent to $3,451 million, but from a much lower base, Actinogen led the percentage rises, up $80 million or 72.1 percent to $191 million, followed by Prescient (47.2%), Cyclopharm (23.9%), Starpharma (17.4%), Proteomics (16.1%) and Alcidion (13.7%).

Clarity led the falls, numerically and by percentage, down $465 million or 25.9 percent to $1,328 million, followed by Medical Developments (25.3%), Medadvisor (22.2%), Micro-X (21.9%), Curvebeam (21.4%), Optiscan (17.6%), Aroa (14.2%), EBR (13.1%), Neuren (12.8%), Polynovo (12.7%), Genetic Signatures (12.0%) and Botanix (11.3%).

Cannabis Corner was up $7 million or 2.5 percent in November to $289 million and up 1.8 percent for the year to November 30. Avecho was the best of the three to rise, up $14 million or 73.7 percent to $33 million, with Neurotech up 5.5 percent and Vitura up 2.3 percent. Bioxyne fell 7.95 percent to $81 million and Little Green lost five percent to $38 million, with six companies unchanged.

On the Nasdaq, Neuphoria (formerly Bionomics) recovered $21 million or 131.25 percent to $37 million, having fallen 48.6 percent the previous month from $35 million to $16 million following another trial showing that BNC210 was not significantly better than placebo for social anxiety disorder.

Kazia climbed 35.0 percent to $27 million, Eyepoint (Psivida) was up 16.0 percent to $1,875 million, Queensland’s Protagonist was up 14.9 percent to $8,589 million; with Redhill down 14.3 percent to $6 million and Incannex losing 11.2 percent to $190 million.

4D Medical has been promoted from the Second 20 to the BDI-20. Lumos has been promoted from the Third 20 to the Second 20. Genetic Signatures has been moved from the BDI-20 to the Third 20. Several others are being watched very carefully.